Chongqing Pharscin Pharmaceutical Co., Ltd.: history, ownership, mission, how it works & makes money

Founded in 1996, Chongqing Pharscin Pharmaceutical Co., Ltd. (ticker 002907.SZ, listed in 2017) has grown from a domestic drugmaker into an innovation-driven firm that in 2019 aimed to meet EMA/FDA cGMP standards, established a U.S. subsidiary (Pharscin US Inc.) in 2023, and by December 2024 employed 1,384 staff (down 27 year-over-year); financially the company reported a market capitalization of approximately CNY 6.48 billion as of December 12, 2025, completed a rights offering of SGD 273 million in July 2025 that materially diluted shareholders, declared a cash dividend of CNY 0.35 per share for H1 2025 payable September 9, 2025, operates debt-free versus a 20.9% debt-to-equity ratio five years earlier, trades at a P/E of 86.90 (August 2025) with a dividend yield of 0.64% and payout ratio of 0.18%, commercializes tablets, powders, granules, soft capsules and injections across 31 provinces reaching over 4,000 public hospitals and more than 8 million patients annually, and positions itself to shift from "Made in China" to "Created in China" through GMP compliance, modern manufacturing and logistics, and nationwide marketing and regulatory expertise.

Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ): Intro

• Established: 1996
• Stock exchange listing: Shenzhen Stock Exchange, ticker 002907 (2017)
• Employees: 1,384 as of Dec 2024 (down 27 from prior year)
• U.S. presence: Pharscin US Inc. established 2023 to facilitate technology transfer and market access

• Manufacturing and sales of sterile injectables, lyophilized powders and finished dosage forms to hospitals, distributors and institutional buyers - core revenue driver.
• Active Pharmaceutical Ingredients (APIs) production and internal use or external sales - margin optimization through vertical integration.
• Contract manufacturing and OEM services for domestic and international pharmaceutical companies.
• Domestic hospital tenders and public procurement contracts - predictable volume-based income stream.
• Export sales and international partnerships enabled by pursuing EMA/FDA cGMP conformity and via Pharscin US Inc.
• Licensing, technology transfer fees and collaboration income from R&D partnerships.

• Regulatory alignment: pursuit of EMA/FDA cGMP to support export and multinational partnerships (initiated 2019).
• Hospital channel penetration and tender success for injectable products.
• R&D investment to develop higher-value sterile and biologic-adjacent products and to support lifecycle extensions.
• Internationalization via Pharscin US Inc. to attract advanced molecules, licensing deals and U.S. market access.

Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ): History

• Listed on the Shenzhen Stock Exchange under ticker 002907.SZ.
• Completed a rights offering in July 2025 of SGD 273 million, resulting in substantial shareholder dilution.
• Transitioned from modest leverage five years ago to a debt-free balance sheet as of 2025.

• Publicly traded company with free float and institutional shareholders; strategic shareholders hold concentrated stakes but were diluted after the July 2025 rights offering.
• Market capitalization approximately CNY 6.48 billion (as of 12 Dec 2025).
• Investor sentiment reflected in a high P/E of 86.90 (Aug 2025), indicating growth expectations.

• Mission: develop and commercialize differentiated pharmaceutical products that address unmet medical needs while generating sustainable shareholder returns.
• How it makes money:
  • Sales of proprietary and licensed drugs (domestic and export markets).
  • Contract manufacturing and CMO services for other pharma companies.
  • Out-licensing and milestone payments tied to R&D progress.

Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ): Ownership Structure

• Mission and values: prioritize innovation, quality, regulatory compliance, and market expansion.
• Quality stance: regards product quality as life and adheres strictly to Chinese GMP standards.
• Regulatory ambition: actively pursuing EMA/FDA cGMP alignment to access global markets.
• Policy expertise: deep institutional knowledge of Chinese pharmaceutical regulation and practical experience managing complex government interactions.
• Commercial footprint: a dedicated marketing and sales force covering all 31 provinces and autonomous regions in China.

• R&D pipeline: internal discovery and formulation work plus tech-transfer partnerships to scale promising candidates.
• Manufacturing: API and finished-dose production in GMP-certified facilities, with an upgrade roadmap toward EMA/FDA cGMP.
• Sales and distribution: branded products and contract manufacturing sales through an in-house sales team and regional distributors.
• Revenue streams: domestic drug sales (branded generics and specialty products), contract manufacturing (CMO), and export development as regulatory approvals permit.

• Major shareholders include founding management, institutional investors, and several state-related investment vehicles (typical for mid-cap Chinese pharmas).
• Board structure mixes executive management with independent directors to support compliance and overseas expansion goals.
• Ownership concentration: top 10 shareholders hold a material portion of shares, aligning strategic continuity with market discipline.

• Current certifications: national GMP compliance for domestic production sites.
• Planned certifications: roadmaps in place to meet EMA and FDA cGMP, including facility upgrades and documentation harmonization.
• Risk management: established protocols and prior experience engaging regulatory authorities; contingency frameworks for policy-driven market shifts.

Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ): Mission and Values

• End-to-end R&D and manufacturing: discovery and formulation teams advance candidates from preclinical work to commercial production, with regulatory filings managed for the Chinese market and select overseas registrations.
• Dosage forms produced: tablets, powders, granules, soft capsules and injections to serve both hospital and retail channels.
• Therapeutic focus areas:
  • Central nervous system (CNS)
  • Digestive system
  • Otolaryngology (ENT)
  • Oncology (supportive care and selected therapeutics)
  • Cardiovascular and cerebrovascular diseases
• Manufacturing automation: a fully automatic intelligent Chinese medicine traditional extraction production line supports standardized extraction and formulation of herbal-derived APIs and intermediates.
• Supply chain and logistics: a modern warehousing and logistics center provides temperature‑controlled storage, batch traceability and outbound distribution to hospital, pharmacy and wholesale customers.
• International technology transfer: Pharscin has established a U.S. subsidiary, Pharscin US Inc., to introduce advanced medical research technology, facilitate regulatory liaison and support licensing/in‑licensing activities.

• Product sales: revenue from finished dosage forms sold through hospital tenders, pharmacies, and distributors across China.
• Contract manufacturing and OEM: third‑party production agreements leveraging automated lines and traditional-extraction capability.
• Licensing and partnerships: income from technology transfers, out‑licensing of formulations and co-development agreements (domestic and international).
• Export sales: targeted exports and cross‑border partnerships managed via the U.S. subsidiary and overseas distributors.
• R&D-driven pipeline value: long-term value capture through approved NCEs/innovative formulations and proprietary traditional Chinese medicine (TCM) preparations.

• Hospital tenders and institutional procurement: primary channel for injections and hospital-use products.
• Retail pharmacies and OTC distribution: tablets, granules and soft capsules positioned for community pharmacies and TCM channels.
• Distributors and wholesalers: regional partners for nationwide coverage; export partners for overseas markets.
• Direct B2B / OEM customers: contract manufacturing for other pharmaceutical firms.

• Dual focus on improved generics and proprietary TCM formulations to balance short‑term cash generation with longer‑term IP value.
• Use of the U.S. subsidiary to access advanced method development, preclinical models and regulatory expertise for potential international filings.
• Continuous process improvement via automation (intelligent extraction) to reduce batch variability, improve yields and lower COGS.

• Hospital groups and provincial tendering authorities for product listing and formulary inclusion.
• Domestic distributors for retail and regional coverage; specialized export partners for overseas markets.
• Academic and contract research organizations (CROs) for clinical studies and regulatory support.

Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ): How It Works

• Primary revenue source: direct sales of pharmaceutical products to hospitals, distributors and healthcare institutions across China.
• Product formats: tablets, powders, granules and injections supplied under in-house brands and licensed/regulatory-approved SKUs.
• Therapeutic focus: treatments for central nervous system (CNS) disorders and cardiovascular diseases, alongside other therapeutic areas.
• Commercial footprint: a professional marketing and sales team covering 31 provinces and autonomous regions, supporting both hospital tendering and distribution networks.

• Manufacturing scale: in-house production of multiple dosage forms reduces per-unit cost and supports margin retention.
• Hospital tenders and procurement: securing place on hospital formularies and winning public procurement tenders drives large-volume, repeat orders.
• Field sales and marketing: a province-level sales force engages prescribers, pharmacists and hospital procurement departments to drive adoption and maintain SKU penetration.
• Distribution partners: regional distributors expand last-mile reach to hospitals and clinics, complementing direct sales.

• Product mix - higher-margin proprietary formulations and injection products typically contribute disproportionately to gross margin.
• Scale and utilization - higher factory utilization lowers fixed-cost per unit, improving gross margins as volumes rise.
• Pricing & reimbursement - placement on provincial and national procurement lists affects average selling prices and volume stability.
• R&D pipeline & approvals - new product approvals expand treatable indications and can lift mid-term revenue growth.

Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ): How It Makes Money

• Core revenue drivers: proprietary small-molecule drugs and generics, contract manufacturing (CMO), and licensing/royalty income from partnered products.
• Commercialization strength: a professional marketing and sales team covering all 31 provinces and autonomous regions in China, enabling wide hospital and retail channel penetration.
• Regulatory edge: strong in-house regulatory affairs capability; anticipated compliance with cGMP standards of EMA and FDA in 2019 to support exports and higher-margin markets.
• Government engagement: deep experience interacting with provincial and national health authorities, aiding product registration, procurement inclusion, and tender navigation.

• Future outlook: commercialization scalability and international cGMP alignment aim to increase export revenue and access to higher-margin markets; domestic policy navigation remains a competitive moat.
• Investor reference: Exploring Chongqing Pharscin Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?